Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 1, 2012
|
| In: |
International journal of oncology
Year: 2012, Volume: 41, Issue: 6, Pages: 2093-2102 |
| ISSN: | 1791-2423 |
| DOI: | 10.3892/ijo.2012.1648 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.3892/ijo.2012.1648 Verlag, Volltext: http://www.spandidos-publications.com/ijo/41/6/2093/abstract 
|
| Author Notes: | Karl Quint, Manuel Tonigold, Pietro Di Fazio, Roberta Montalbano, Susanne Lingelbach, Felix Rückert, Beate Alinger, Matthias Ocker and Daniel Neureiter |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1575062526 | ||
| 003 | DE-627 | ||
| 005 | 20220814141348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180515s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/ijo.2012.1648 |2 doi | |
| 035 | |a (DE-627)1575062526 | ||
| 035 | |a (DE-576)505062526 | ||
| 035 | |a (DE-599)BSZ505062526 | ||
| 035 | |a (OCoLC)1341009481 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Quint, Karl |e VerfasserIn |0 (DE-588)115959662X |0 (DE-627)1022977784 |0 (DE-576)505062992 |4 aut | |
| 245 | 1 | 0 | |a Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition |c Karl Quint, Manuel Tonigold, Pietro Di Fazio, Roberta Montalbano, Susanne Lingelbach, Felix Rückert, Beate Alinger, Matthias Ocker and Daniel Neureiter |
| 264 | 1 | |c October 1, 2012 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.05.2018 | ||
| 500 | |a Abstract: Objective response rates to standard chemotherapeutic regimens remain low in pancreatic cancer. Subpopulations of cells have been identified in various solid tumors which express stem cell-associated markers and are associated with increased resistance against radiochemotherapy. We investigated the expression of stem cell genes and markers of epithelial-mesenchymal transition in pancreatic cancer cells that survived high concentrations of gemcitabine treatment. Capan-1 and Panc-1 cells were continuously incubated with 1 and 10 µM gemcitabine. Surviving cells were collected after 1, 3 and 6 days. Expression of PDX-1, SHH, CD24, CD44, CD133, EpCAM, CBX7, OCT4, SNAIL, SLUG, TWIST, Ki-67, E-cadherin, β-catenin and vimentin were quantified by qPCR or immunocytochemistry. Migration was assessed by wound‑healing assay. SHH was knocked down using RNA interference. Five primary pancreatic cancer cell lines were used to validate the qPCR results. All investigated genes were upregulated after 6 days of gemcitabine incubation. Highest relative expression levels were observed for OCT4 (13.4-fold), CD24 (47.3-fold) and EpCAM (15.9-fold) in Capan-1 and PDX-1 (13.3‑fold), SHH (24.1-fold), CD44 (17.4-fold), CD133 (20.2-fold) and SLUG (15.2-fold) in Panc-1 cells. Distinct upregulation patterns were observed in the primary cells. Migration was increased in Panc-1 cells and changes in the expression of E-cadherin and β-catenin were typical of epithelial-mesenchymal transition in both cell lines. SHH knockdown reduced IC50 from 30.1 to 27.6 nM in Capan-1 while it strongly inhibited proliferation in Panc-1 cells. Cells surviving high-dose gemcitabine treatment express increased levels of stem cell genes, show characteristics associated with epithelial-mesenchymal transition and retain their proliferative capacity | ||
| 700 | 1 | |a Rückert, Felix |d 1978- |e VerfasserIn |0 (DE-588)130606332 |0 (DE-627)504638017 |0 (DE-576)298294230 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of oncology |d Athens : Spandidos Publ., 1992 |g 41(2012), 6, Seite 2093-2102 |h Online-Ressource |w (DE-627)348586272 |w (DE-600)2079608-0 |w (DE-576)271585528 |x 1791-2423 |7 nnas |a Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition |
| 773 | 1 | 8 | |g volume:41 |g year:2012 |g number:6 |g pages:2093-2102 |g extent:10 |a Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/ijo.2012.1648 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.spandidos-publications.com/ijo/41/6/2093/abstract |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180515 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 130606332 |a Rückert, Felix |m 130606332:Rückert, Felix |d 60000 |d 61800 |e 60000PR130606332 |e 61800PR130606332 |k 0/60000/ |k 1/60000/61800/ |p 6 | ||
| 999 | |a KXP-PPN1575062526 |e 3009328338 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"role":"aut","roleDisplay":"VerfasserIn","given":"Karl","display":"Quint, Karl","family":"Quint"},{"family":"Rückert","display":"Rückert, Felix","given":"Felix","roleDisplay":"VerfasserIn","role":"aut"}],"relHost":[{"id":{"issn":["1791-2423"],"zdb":["2079608-0"],"eki":["348586272"]},"part":{"volume":"41","issue":"6","text":"41(2012), 6, Seite 2093-2102","pages":"2093-2102","extent":"10","year":"2012"},"recId":"348586272","note":["Volltext auch als Teil einer Datenbank verfügbar","Gesehen am 12.06.2025"],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["Volume 1, issue 1 (June 1992)-"],"title":[{"title":"International journal of oncology","title_sort":"International journal of oncology"}],"disp":"Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transitionInternational journal of oncology","language":["eng"],"origin":[{"dateIssuedDisp":"[1992]-","publisher":"Spandidos Publ. ; Univ. of Crete","publisherPlace":"Athens ; Heraklion"}],"name":{"displayForm":["University of Crete, Faculty of Medicine, Laboratory of Clinical Virology"]},"physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["Karl Quint, Manuel Tonigold, Pietro Di Fazio, Roberta Montalbano, Susanne Lingelbach, Felix Rückert, Beate Alinger, Matthias Ocker and Daniel Neureiter"]},"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"October 1, 2012"}],"id":{"doi":["10.3892/ijo.2012.1648"],"eki":["1575062526"]},"physDesc":[{"extent":"10 S."}],"title":[{"title_sort":"Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition","title":"Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1575062526","note":["Gesehen am 15.05.2018","Abstract: Objective response rates to standard chemotherapeutic regimens remain low in pancreatic cancer. Subpopulations of cells have been identified in various solid tumors which express stem cell-associated markers and are associated with increased resistance against radiochemotherapy. We investigated the expression of stem cell genes and markers of epithelial-mesenchymal transition in pancreatic cancer cells that survived high concentrations of gemcitabine treatment. Capan-1 and Panc-1 cells were continuously incubated with 1 and 10 µM gemcitabine. Surviving cells were collected after 1, 3 and 6 days. Expression of PDX-1, SHH, CD24, CD44, CD133, EpCAM, CBX7, OCT4, SNAIL, SLUG, TWIST, Ki-67, E-cadherin, β-catenin and vimentin were quantified by qPCR or immunocytochemistry. Migration was assessed by wound‑healing assay. SHH was knocked down using RNA interference. Five primary pancreatic cancer cell lines were used to validate the qPCR results. All investigated genes were upregulated after 6 days of gemcitabine incubation. Highest relative expression levels were observed for OCT4 (13.4-fold), CD24 (47.3-fold) and EpCAM (15.9-fold) in Capan-1 and PDX-1 (13.3‑fold), SHH (24.1-fold), CD44 (17.4-fold), CD133 (20.2-fold) and SLUG (15.2-fold) in Panc-1 cells. Distinct upregulation patterns were observed in the primary cells. Migration was increased in Panc-1 cells and changes in the expression of E-cadherin and β-catenin were typical of epithelial-mesenchymal transition in both cell lines. SHH knockdown reduced IC50 from 30.1 to 27.6 nM in Capan-1 while it strongly inhibited proliferation in Panc-1 cells. Cells surviving high-dose gemcitabine treatment express increased levels of stem cell genes, show characteristics associated with epithelial-mesenchymal transition and retain their proliferative capacity"]} | ||
| SRT | |a QUINTKARLRPANCREATIC1201 | ||